All In Biotech

Drug Trial Radar · NCT07252739

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Nov 15, 2029

Study completion May 31, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

Conditions

  • Malignant Neoplasm

Interventions

  • MK-1084Drug

    Oral Administration

  • PembrolizumabBiological

    Intravenous administration

  • CetuximabBiological

    Intravenous administration

  • Sacituzumab tirumotecan (sac-TMT)Biological

    Injection powder for intravenous infusion

  • Rescue medicationDrug

    Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 \[Hl\] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with a Dose Limiting Toxicity (DLT)Time frame: Up to approximately 21 days
  2. Percentage of Participants who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 84 months
  3. Percentage of Participants who Discontinue Study Intervention Due to an AETime frame: Up to approximately 84 months
  4. Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 84 months

Locations

40 sites in 14 countries. Site status is shown where the registry gives one.

  • Clermont Oncology Center ( Site 0041)

    Clermont, Florida · Recruiting

  • Sanford Health Roger Maris Cancer Center ( Site 0039)

    Fargo, North Dakota · Recruiting

  • Sanford Cancer Center Oncology Clinic ( Site 0038)

    Sioux Falls, South Dakota · Recruiting

  • Fundacion Arturo Lopez Perez ( Site 0167)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Centro de Oncología de Precisión ( Site 0160)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0168)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)

    Nanjing, Jiangsu, China · Recruiting

  • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)

    Nanchang, Jiangxi, China · Recruiting

  • Zhongshan Hospital Fudan University ( Site 0319)

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital, Sichuan University ( Site 0315)

    Chengdu, Sichuan, China · Recruiting

  • Kuopion Yliopistollinen Sairaala ( Site 0261)

    Kuopio, Northern Savonia, Finland · Recruiting

  • Vaasan Keskussairaala ( Site 0263)

    Vaasa, Pohjanmaa, Finland · Recruiting

  • Turku University Hospital ( Site 0262)

    Turku, Southwest Finland, Finland · Recruiting

  • HYKS Syöpätautien klinikka ( Site 0260)

    Helsinki, Uusimaa, Finland · Recruiting

  • Evangelismos General Hospital of Athens ( Site 0200)

    Athens, Attica, Greece · Recruiting

  • Hong Kong Integrated Oncology Centre ( Site 0232)

    Central, Hong Kong · Recruiting

  • Queen Mary Hospital ( Site 0230)

    Hong Kong, Hong Kong · Recruiting

  • Hong Kong United Oncology Centre ( Site 0231)

    Kowloon, Hong Kong · Recruiting

  • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)

    Milan, Lombardy, Italy · Recruiting

  • Deventer Ziekenhuis ( Site 0272)

    Deventer, Overijssel, Netherlands · Recruiting

  • Leids Universitair Medisch Centrum ( Site 0273)

    Leiden, South Holland, Netherlands · Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Severance Hospital Yonsei University Health System ( Site 0080)

    Seoul, South Korea · Recruiting

  • Hospital Universitario Virgen de la Macarena ( Site 0093)

    Seville, Spain · Recruiting

  • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)

    Bangkok, Bangkok, Thailand · Recruiting

  • Faculty of Medicine Siriraj Hospital ( Site 0350)

    Bangkok, Bangkok, Thailand · Recruiting

  • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)

    Adana, Turkey (Türkiye) · Recruiting

  • Koç Üniversitesi Hastanesi ( Site 0142)

    Adana, Turkey (Türkiye) · Recruiting

  • Liv Hospital Ankara ( Site 0146)

    Ankara, Turkey (Türkiye) · Recruiting

  • Hacettepe Universite Hastaneleri ( Site 0140)

    Ankara, Turkey (Türkiye) · Recruiting

  • Erciyes University ( Site 0145)

    Talas, Kayseri, Turkey (Türkiye) · Recruiting

  • VISION PARTNER Medical Centre ( Site 0135)

    Kyiv, Ukraine · Active not recruiting

  • LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)

    Kyiv, Ukraine · Recruiting

  • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)

    Cherkasy, Cherkasy Oblast, Ukraine · Recruiting

  • Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)

    Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine · Recruiting

  • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine · Recruiting

  • Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)

    Kropyvnytskyi, Kirovohrad Oblast, Ukraine · Recruiting

  • Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)

    Lviv, Lviv Oblast, Ukraine · Recruiting

  • Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)

    Vinnitsya, Vinnytsia Oblast, Ukraine · Recruiting

  • Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)

    Uzhhorod, Zakarpattia Oblast, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.